Integra LifeSciences Appoints Kenneth Burhop, Ph.D., as Corporate Vice President and Chief Scientific Officer
PLAINSBORO, N.J., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that Kenneth Burhop has joined Integra as Corporate Vice President, Chief Scientific Officer. Dr. Burhop will be responsible for setting Integra's strategic scientific vision and roadmap, and will lead the Company's portfolio prioritization and management, and the scientific evaluation of corporate development and new product opportunities.
"I am delighted that Ken has joined Integra," said Mr. Arduini, Integra's President and Chief Executive Officer. "With over 30 years of experience in research, development, and commercialization, Ken brings a depth of scientific leadership that will be critical as we continue to expand our product pipeline."
One of Integra's strategic goals is accelerating growth. To achieve that, Integra is optimizing its growth efforts through a combination of product line extensions, organic product development and the in-licensing and acquisition of technology. In particular, Integra's key differentiating strength is in regenerative medicine. Under Dr. Burhop's leadership, Integra will continue clinical and regenerative R&D capabilities to accelerate the Company's efforts in these areas.
"I am excited to join Integra to lead our R&D efforts and advance our growth strategy forward," said Dr. Burhop, Ph.D., Integra's Corporate Vice President and Chief Scientific Officer. "We have an opportunity to develop and commercialize exciting new technologies in regenerative medicine, as well as optimize our overall portfolio management across our business segments."
Dr. Burhop authored over 40 publications and 70 abstracts and holds several patents. He is a scientific expert in a wide variety of research areas, including wound healing and wound dressing development. He has extensive experience in both biotechnology and medical device R&D, including the development of biocompatible materials, pharmaceuticals and biopharmaceuticals, and electromechanical devices.
Dr. Burhop was most recently Chief Scientific Officer at Sangart, Inc. Prior to joining Sangart, he spent over 20 years with Baxter Healthcare Corporation in a series of leadership roles, including most recently, Vice President, R&D, Baxter Pharmaceutical Technologies. Prior to that, Dr. Burhop was Vice President/Global Scientific Lead (CSO) for Baxter's Medication Delivery Division, a business with over $4 billion in annual sales. As CSO, he provided leadership and direction for all Medication Delivery R&D and product support across the division's five strategic businesses.
Dr. Burhop received his Ph.D. and M.S. in Veterinary Science from the University of Wisconsin-Madison, and his B.A. in Zoology from University of Wisconsin-Milwaukee.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences:
Media
Gianna Sabella
609-936-2389
gianna.sabella@integralife.com
Investors
Angela Steinway
609-936-2268
angela.steinway@integralife.com